We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+10.75%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3B
AUM Growth
-$85.7M
(-2.8%)
Cap. Flow
-$518M
Cap. Flow
% of AUM
-17.24%
Top 10 Holdings %
Top 10 Hldgs %
35.54%
Holding
152
New
30
Increased
26
Reduced
33
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$60.8M |
| 2 |
ALPN
Alpine Immune Sciences Inc
ALPN
|
+$55.6M |
| 3 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$40.9M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$39.9M |
| 5 |
DYAX
DYAX CORPORATION
DYAX
|
+$35.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
+$446M |
| 2 |
AbbVie
ABBV
|
+$89.8M |
| 3 |
ADVM
Adverum Biotechnologies
ADVM
|
+$85.8M |
| 4 |
BLUE
bluebird bio
BLUE
|
+$47.9M |
| 5 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$27.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.77% |
| 2 | Financials | 3.42% |
| 3 | Technology | 0.52% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ESPR
101
DELISTED
Esperion Therapeutics
ESPR
| $1.71M | 0.06% |
20,900
+18,400
| +736% | +$1.8M |
|
102
CareDx
CDNA
$1.99B
| $1.49M | 0.05% |
229,000
-575,000
| -72% | -$3.12M |
|
|
KND
103
DELISTED
Kindred Healthcare
KND
| $1.42M | 0.05% |
+70,114
| New | +$1.61M |
|
|
ASXC
104
DELISTED
Asensus Surgical, Inc.
ASXC
| $884K | 0.03% |
+22,667
| New | +$1.04M |
|
105
Ironwood Pharmaceuticals
IRWD
$637M
| $768K | 0.03% |
+76,058
| New | +$884K |
|
106
Perrigo
PRGO
$1.47B
| $647K | 0.02% |
+3,500
| New | +$667K |
|
|
POZN
107
DELISTED
POZEN INC
POZN
| $460K | 0.02% |
+44,583
| New | +$367K |
|
108
EyePoint Inc
EYPT
$1.07B
| $388K | 0.01% |
+10,282
| New | +$409K |
|
|
RCPT
109
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $380K | 0.01% |
+2,000
| New | +$331K |
|
110
Ascendis Pharma A/S
ASND
$16.6B
| $369K | 0.01% |
20,859
-179,141
| -90% | -$3.13M |
|
|
111
AbbVie
ABBV
$447B
| – | – |
-1,534,000
| Closed | -$89.8M |
|
112
Abeona Therapeutics
ABEO
$372M
| – | – |
-13,996
| Closed | -$1.1M |
|
113
Abbott
ABT
$177B
| – | – |
-13,000
| Closed | -$602K |
|
114
Acadia Pharmaceuticals
ACAD
$4.33B
| – | – |
-49,400
| Closed | -$1.61M |
|
|
ADVM
115
DELISTED
Adverum Biotechnologies
ADVM
| – | – |
-211,747
| Closed | -$85.8M |
|
116
Alkermes
ALKS
$8.67B
| – | – |
-17,500
| Closed | -$1.07M |
|
117
Cross Country Healthcare
CCRN
$428M
| – | – |
-366,724
| Closed | -$4.35M |
|
|
CLLS
118
Cellectis
CLLS
$267M
| – | – |
-150,506
| Closed | -$5.2M |
|
119
PUT
Gilead Sciences
GILD
$165B
| – | – |
-200,000
| Closed | -$19.6M |
|
120
Illumina
ILMN
$28B
| – | – |
-6,579
| Closed | -$1.19M |
|
|
LITS
121
Lite Strategy Inc
LITS
$35M
| – | – |
-40,128
| Closed | -$1.44M |
|
122
Nektar Therapeutics
NKTR
$2.2B
| – | – |
-3,040
| Closed | -$502K |
|
123
Tempest Therapeutics
TPST
$15M
| – | – |
-139
| Closed | -$14.1M |
|
124
Travere Therapeutics
TVTX
$5.18B
| – | – |
-158,223
| Closed | -$3.79M |
|
125
TherapeuticsMD
TXMD
$24M
| – | – |
-44,466
| Closed | -$13.5M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q2 2015 Portfolio in Review
As of Q2 2015, Deerfield Management held 152 positions worth $3B, down 2.8% from $3.09B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Deerfield Management withdrew a net $518M in Q2 2015, closing 32 positions and reducing 33 holdings. Its most notable exit was AUSPEX PHARMACEUTICALS INC COM STK (DE), an estimated $446M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 60% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in Alpine Immune Sciences Inc worth $56.5M.
- Deerfield Management's largest Q2 2015 buy was Alpine Immune Sciences Inc: 933,103 shares worth $56.5M.
- Deerfield Management added most to Viatris in Q2 2015, an estimated $60.8M increase.
- Deerfield Management's biggest Q2 2015 reduction was bluebird bio, cutting an estimated $47.9M.
- Deerfield Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $446M.
- Deerfield Management's ten largest holdings make up 36% of its $3B portfolio in Q2 2015.
- Deerfield Management opened 30 new positions and closed 32 in Q2 2015.
- Deerfield Management's portfolio value fell 2.8% quarter-over-quarter to $3B.
Based on Deerfield Management's 13F filing for Q2 2015, filed 14 Aug 2015.